University of California San Francisco
Give to UCSF
Learn about UCSF’s response to the coronavirus outbreak, important updates on campus safety precautions, and the latest policies and guidance on our COVID-19 resource website. You can also access information from the CDC. Learn more
UCSF and BridgeBio Pharma, Inc. today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.
A group at Gladstone Institutes and UCSF has demonstrated that a large-scale and systematic genetic approach can indeed yield reliable and detailed information on the structure of protein complexes.
We asked several UCSF experts for a personal take on what will convince them that a vaccine is safe.
Giant lizards with superpowered hearts. Hairless rodents that don’t seem to age. Songbirds that babble like human babies. These and other scurrying, soaring, and slithering wonders are teaching scientists how our own bodies work – and how to fix them.
In the new study, UCSF researchers showed rapid restoration of youthful cognitive abilities in aged mice, accompanied by a rejuvenation of brain and immune cells that could help explain improvements in brain function.
Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research.
SARS-CoV-2 uses its distinctive spike to latch onto a receptor called ACE2 on the surface of a human cell. Once there it prompts the human cell to ferry the virus inside. Then, the virus co-opts human enzymes to make copies of itself and spread to other cells.
For a tiny embryo to develop into an adult organism, its cells must develop in precise patterns and interact with their neighbors in carefully orchestrated ways. To create complex tissues and organs –
An international team of researchers studied the three lethal coronaviruses SARS-CoV-2, SARS-CoV-1 and MERS-CoV in order to identify commonly hijacked cellular pathways and detect promising targets for broad coronavirus inhibition.
Researchers at UCSF are tackling antibiotic resistance using a different approach: redesigning existing antibiotic molecules to evade a bacterium’s resistance mechanisms
UCSF scientists have devised a novel approach to halting the spread of SARS-CoV-2, the virus that causes the disease.
Some supposedly inert ingredients in common drugs — such as dyes and preservatives — may potentially be biologically active and could lead to unanticipated side effects, according to a preliminary new study by researchers from the UCSF and the Novartis Institutes for BioMedical Research.
UCSF researchers have now determined how the TRPA1 molecule manages to sense such a diverse variety of dangerous chemicals – and do so with enough sensitivity to let you flee before suffering too much tissue damage.
Joel Ernst, MD, addresses key questions about how vaccine development works and why vaccines are especially important in the case of COVID-19.
Why are more men than women dying of COVID-19? Scientist Faranak Fattahi, PhD, has found a clue.
Scientists have identified key chemical building blocks for an eventual antiviral drug against SARS-CoV-2, the virus that causes COVID-19.
The nationwide clinical trial will assess whether the common antibiotic azithromycin can reduce hospitalization stays and death caused by the SARS-CoV-2 virus.
Under a new agreement, Celgene will further invest in the RAN’s state-of-the-art antibody engineering program to expand target discovery from oncology and immunology to include neurology.
UCSF researchers have become to the first to solve the structure of a hard-working protein that helps reload neurons for repeated firing.
An international team of more than 120 scientists has detailed the impact of 75 over-the-counter prescription and development-stage drug compounds on SARS-CoV-2, the virus that causes COVID-19.
As people around the world try to envision recovery from the COVID-19 pandemic, much attention has been paid to antibody testing as a way to identify people who have developed immunity to the virus. UCSF experts explain how antibody testing works, who it can be most useful for and why we should be cautious.
UCSF is recruiting newly diagnosed COVID-19 patients for a large global clinical trial testing whether the common anti-inflammatory drug colchicine can reduce hospitalization and death caused by the illness.
Though many hopes are hanging on the development of a vaccine or drug that targets the novel coronavirus directly, a UCSF-led team is taking an unconventional approach: target the host – in other words, you.
